Amoy Diagnostics Co., Ltd.

Shenzhen Stock Exchange 300685.SZ

Amoy Diagnostics Co., Ltd. EBIT for the year ending December 31, 2023: USD 41.70 M

Amoy Diagnostics Co., Ltd. EBIT is USD 41.70 M for the year ending December 31, 2023, a -3.23% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Amoy Diagnostics Co., Ltd. EBIT for the year ending December 31, 2022 was USD 43.09 M, a 8.83% change year over year.
Amoy Diagnostics Co., Ltd. EBIT for the year ending December 31, 2021 was USD 39.60 M, a 28.85% change year over year.
Amoy Diagnostics Co., Ltd. EBIT for the year ending December 31, 2020 was USD 30.73 M, a 27.49% change year over year.
Amoy Diagnostics Co., Ltd. EBIT for the year ending December 31, 2019 was USD 24.10 M, a 16.77% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

Shenzhen Stock Exchange: 300685.SZ

Amoy Diagnostics Co., Ltd.

CEO	Ms. Ying Chen
IPO Date	Aug. 3, 2017
Location	China
Headquarters	39 Dingshan Road
Employees	1,119
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Amoy Diagnostics Co., Ltd., a diagnostic company, focuses on molecular diagnostics for oncology precision medicine in China and internationally. The company offers NGS, real-time PCR, FISH, and extraction assays. Amoy Diagnostics Co., Ltd. was founded in 2008 and is based in Xiamen, China.

Key trends

Past 5 years